Ocumetics Technology Corp. (TSXV:OTC, OTCQB:OTCFF, FRA:2QBO) focuses on a groundbreaking vision enhancement product - the Ocumetics Accommodating Lens. Leading the forefront of research and product development, Ocumetic's intraocular lens (IOL) is engineered to seamlessly shift the eye's focus from close to far distances without any noticeable lag. This process is called accommodation.
The eye's natural lens loses its flexibility to bend light rays accurately due to aging and injuries. This leads to the deterioration of eyesight and potential conditions like cataracts with or without astigmatism. Ocumetics has designed a very unique IOL that is surgically implanted to restore a patient’s vision. This lens is designed to harmoniously align with the eye's natural mechanisms, enhancing vision by appropriately bending light rays. Notably, it's designed to last a lifetime, presenting a significant potential advancement over other cataract technologies.
Ocumetics aims to solve the problem of eyesight degradation. The proposed solution is a surgically implanted lens that takes over the function of properly bending rays of light by working with the eye’s natural mechanisms, resulting in enhanced vision. Following a series of product enhancements, development of surgical procedure protocols, and animal testing for biocompatibility, the Ocumetics Accommodating Lens will soon begin human trials as the company works toward bringing the product to market.
This Ocumetics Technology profile is part of a paid investor education campaign.*
(TheNewswire)
 | |||||||||
 |  | ||||||||
Calgary, Alberta May 24, 2024 - TheNewswire . Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Calgary, Alberta TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023. The new closing deadline for the private placement is January 15, 2024.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
| |||||||||
| | ||||||||
Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic
Dean Burns, CEO of Ocumetics and 27-year Alcon veteran, will lead the presentation.
Click Image To View Full Size
Join the webinar to:
Learn more about the significance of the biocompatibility animal study;
Learn more about the upcoming first-in-human study; and
Ask questions regarding the Ocumetics Accommodating Lens and the company's plans.
Details are as follows:
Date: December 20, 2023
Time: 18:00 EST
RSVP: https://ocumetics.com/webinar-december-20-2023/
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated to developing and commercializing advanced vision correction solutions that enhance the quality of life for individuals worldwide.
Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. In its pursuit of a next generation interocular lens solution, Ocumetics has developed the Ocumetics Accommodating Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to seamlessly shift focus from distance to intermediate to near.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dean Burns
President and CEO
(817) 874-7564
Dayton Marks
Director
(778) 347-2500
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.
During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 023107. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials." A replay of the call will be available under "News, Events & Presentations" through Wednesday, August 7, 2024.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240702216999/en/
Media:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
News Provided by Business Wire via QuoteMedia
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc.
"On behalf of our employees, our executive committee and our board of directors, I want to thank Karen for her leadership over the last eight years. I am personally grateful to Karen for her support through my transition to CEO, navigating the pandemic and delivering a new operating model for the company. We wish her all the best as she takes on the next chapter of her career," said Geoff Martha , Medtronic chairman and chief executive officer. "Across the company, we're building momentum with our innovation-driven growth strategy, and we remain focused and committed to delivering on our short- and longer-term financial objectives."
"It has been a pleasure to serve Medtronic and our Mission for the last eight years," said Parkhill. "I am grateful to have had the opportunity to lead the outstanding finance team at Medtronic, and I know they will continue to deliver on our commitments. I remain excited about the plans Medtronic has for the future, and most of all, the huge impact Medtronic technologies will have on the lives of patients around the world."
The company is evaluating internal and external succession candidates. Parkhill will continue to serve as chief financial officer until her departure on August 2 , and Gary Corona , senior vice president, Global Financial Planning and Analysis, will serve as interim chief financial officer upon her departure.
In addition, the company also reaffirmed guidance for its first quarter and full fiscal year 2025, as previously disclosed in its May 23, 2024 , earnings press release and webcast.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn .
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. Medtronic does not undertake to update its forward-looking statements, including to reflect future events or circumstances.
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1 (763) 526-8478 | +1 (763) 505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-announces-departure-of-karen-parkhill-chief-financial-officer-302182527.html
SOURCE Medtronic plc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2024/26/c1704.html
News Provided by Canada Newswire via QuoteMedia
With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84 th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population.
Tackling hyperglycemia to improve long-term health with type 1 diabetes
Among the burdens of living with diabetes, hyperglycemia can often be overshadowed by hypoglycemia. Yet, in the U.S., only 26% of people living with diabetes achieve HbA1c levels of 1 Reducing the time spent with high blood sugars continues to be a significant unmet need as it can lead to serious health problems impacting multiple organs. 2 For children, prolonged highs can have adverse effects on memory, IQ, executive functioning, and learning. 3
One cause of high blood sugars is the dawn phenomenon, an increase in glucose levels in the early morning. 4 This can be a common occurrence for those living with diabetes and may add to feelings of frustration with diabetes. An encouraging new retrospective analysis of real-world data (n= 6026) showed that this morning peak was nearly eliminated for users who upgraded from the MiniMed™ 770G system to the MiniMed™ 780G system. The data assessed the elevation of sensor glucose levels >20 mg/dL from 3 - 6 a.m. compared to 12 – 3 a.m. at least 30% of the nights. The transition from the MiniMed™ 770G system to the MiniMed™ 780G system decreased dawn phenomenon rates from 12.2% to 4.5%. Time in Range also increased from 87.7% to 91.4% from 12 – 6 a.m. , which is consistent with dawn phenomenon trends.
Early and consistent management of hyperglycemia is critical as it has protective effects on the body that can last for decades. 5 "For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control," explained Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "The introduction of the MiniMed™ 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia. 6,7 It's been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey."
Reducing nighttime burden
For individuals living with type 1 diabetes, CGM-generated alerts and the need to deliver manual boluses disrupt sleeping through the night adding to the burden of diabetes. The MiniMed™ 780G system is designed to reduce the burden of diabetes throughout the day and night. Additional real-world data from a retrospective analysis presented at ADA (n=8019; † of glucose levels every 5 minutes, including during sleep. § With the MiniMed™ 780G system, nighttime alerts decreased 45% for all users and 55% for those who used recommended optimal settings. Additionally, uninterrupted sleep, a greatly desired outcome for those living with diabetes, increased by 30 and 36 minutes per night, respectively. These results add to the diabetes burden reduction that MiniMed™ 780G system users experience with an advanced algorithm with frequent, every 5-minute autocorrections.
The continued evolution of the MiniMed™ 780G system to reduce burden
Along with evidence on the currently available MiniMed™ 780G system, additional data will be presented on the next iteration of the system,* which aims to further reduce diabetes management burden through its design. The system is intended to be paired with the Simplera Sync™ sensor, a disposable, all-in-one continuous glucose monitor (CGM) designed to require no overtape.
A 24-site, single arm study evaluated the use of the next iteration of the MiniMed™ 780G system algorithm paired with the Simplera Sync™ sensor. Results were promising across all clinical outcomes metrics including Time in Range (TIR), Time in Tight Range (TITR) and Time Above Range (TAR), compared to the run-in group where hybrid closed loop (auto basal only) or open-loop delivery was used. The study included the use of recommended optimal settings (ROS) (100 mg/dL set target with an active insulin time of 2 hours) related to TIR, TITR, and TAR.
"The MiniMed™ 780G system has firmly established itself as a proven automated insulin delivery system," said study investigator Gregory Forlenza , MD, professor and pediatric endocrinologist at the Barbara Davis Center. "With the next iteration of the system and this next-generation Simplera Sync™ sensor, the overall experience for people living with type 1 diabetes could be enhanced and may prove to be a compelling option for diabetes management — particularly when leveraged in combination with recommended optimal settings."
The MiniMed™ 780G system** is currently available for ages 7 and above in over 100 countries globally and will be launching with the Simplera Sync™ sensor in parts of Europe in late July. Currently, Simplera Sync™ is investigational and not approved for commercial use in the U.S.*
Safety and Glycemic Outcomes Using the MiniMed™ 780G system with an All-in-One | ||||||||
Youths (ages 7-17) | Adults (ages 18-80) | |||||||
Run-in | Study | ROS | Run-in | Study | ROS | |||
Time in Smart Guard, | 14.5 ± 31.3 | 93.5±11.3 | 96.9±3.1 | 33.2±40.3 | 96.6±6.6 | 97.5±3.7 | ||
Mean SG, mg/dL | 180.4±27.1 | 154.4±17.6 | 149.0±15.3 | 161.0±18.7 | 142.2±12.8 | 136.5±12.0 | ||
Percentage of time spent at glucose ranges | ||||||||
(% TBR) | 1.6±1.7 | 1.9±1.4 | 1.9±1.2 | 1.7±1.9 | 1.5±1.4 | 1.7±1.4 | ||
70-140 mg/dL (% TITR) | 32.1±14.1 | 49.2±9.7 | 52.7±9.2 | 39.2±13.0 | 56.1±10.5 | 61.6±9.9 | ||
70-180 mg/dL (% TIR) | 54.4±15.7 | 71.4±9.9 | 74.7±9.3 | 66.5±12.6 | 80.2±8.1 | 83.8±7.4 | ||
>180 mg/dL (% TAR) | 44.0±16.1 | 26.7±10.1 | 23.3±9.4 | 31.8±13.1 | 18.2±8.4 | 14.5±7.7 | ||
Caption: Glycemic metrics and insulin delivered during youth and adult MiniMed™ 780G system investigational use with the disposable all-in-one Simplera Sync™ sensor
To view this data at the 84 th American Diabetes Association (ADA) Scientific Sessions in Orlando, Florida , view the company's previous announcement here for presentation times.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn .
About Medtronic Diabetes ( www.medtronicdiabetes.com )
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
*Investigational. Not approved by the FDA for any use and not commercially available in the US.
**MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§ Refers to SmartGuard™ feature. Individual results may vary.
Contacts: | |
Ashley Patterson | Ryan Weispfenning |
Public Relations | Investor Relations |
+1 (818) 576-3025 | +1 (763) 505-4626 |
View original content to download multimedia: https://www.prnewswire.com/news-releases/new-minimed-780g-system-data-demonstrates-ability-to-address-persistent-blood-sugar-challenges-for-people-with-type-1-diabetes-302179448.html
SOURCE Medtronic plc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2024/21/c5026.html
News Provided by Canada Newswire via QuoteMedia
Sempra (NYSE: SRE) (BMV: SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE: MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry.
"Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infrastructure company," said Jeffrey W. Martin , Sempra chairman and CEO. "Our board of directors embody a diverse set of skills, experiences and viewpoints that help guide Sempra's corporate strategy and overall business success. Jennifer's strong accounting and finance experience, coupled with her understanding of the energy business, will be a great complement to the board as we advance our corporate strategy and oversee financial discipline, risk management and ethical practices."
Before joining Medtronic, Kirk, 49, worked at Occidental Petroleum Corporation for more than two decades, serving in roles of increasing responsibility, including senior vice president of integration and value capture, and vice president, controller and principal accounting officer.
Kirk serves on the board of directors of Republic Services, where she is chair of the audit committee. She holds a bachelor's degree in economics from UC Santa Barbara and a master's degree in business administration from California State University, Bakersfield .
With the appointment of Kirk, Sempra will have 10 directors with three having been newly elected over the past five years, reflecting the company's commitment to periodic board refreshment to ensure fresh and diverse perspectives are present in the boardroom. Kirk will serve on the board's audit committee and the safety, sustainability and technology committee.
About Sempra
Sempra (NYSE: SRE) is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California , Texas , Mexico and global energy markets. The company is recognized as a leader in sustainable business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in the Dow Jones Sustainability Index North America and in The Wall Street Journal's Best Managed Companies. More information about Sempra is available at sempra.com and on social media @Sempra .
View original content to download multimedia: https://www.prnewswire.com/news-releases/sempra-appoints-jennifer-m-kirk-to-board-of-directors-302177421.html
SOURCE Sempra
News Provided by PR Newswire via QuoteMedia
